Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: THC ~2.5% Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863
View directory record Official record
Conditions
Behavioral Pharmacology of Cannabinoids
Interventions
Oral Placebo, Oral THC, Oral CBD, Oral Caffeine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

NCT04374773
View directory record Official record
Conditions
Pregnancy Related, Cannabis Use
Interventions
Dronabinol
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Terminated Phase 1 Interventional

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol 2.5 MG, Microcrystalline cellulose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

NCT03398083
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
THC, Alprazolam, Placebo oral capsule, CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia

NCT03679949
View directory record Official record
Conditions
Pain, Abuse, Drug
Interventions
Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1), Cannabis (THC:CBD = ~ 1:1), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 53 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 17, 2026, 1:55 AM EDT
Withdrawn Phase 2 Interventional

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

NCT02608931
View directory record Official record
Conditions
Nausea, Vomiting, Familial Dysautonomia
Interventions
Dronabinol, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 17, 2026, 1:55 AM EDT
Suspended Phase 2 Interventional

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

NCT05427630
View directory record Official record
Conditions
Migraine, Cannabis, THC
Interventions
THC ~2.5%, THC ~5%, THC ~10%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

NCT01361607
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Glendale, California • Santa Rosa, California • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD Cannabis Extract: Pharmacokinetic Studies

NCT04280289
View directory record Official record
Conditions
Epilepsy
Interventions
cannabidiol extract
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 2Phase 3 Interventional

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

NCT06146101
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Chula Vista, California • Long Beach, California • Upland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

NCT01337089
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
37
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 17, 2026, 1:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

NCT04615949
View directory record Official record
Conditions
COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • Cutler Bay, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Inhaled Cannabis on Driving Performance

NCT01620177
View directory record Official record
Conditions
Alcohol Drinking, Cannabis
Interventions
Alcohol(oral) and placebo, Cannabis(THC)(Inhaled) and Placebo
Drug
Lead sponsor
Gary R Gaffney
Other
Eligibility
21 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

NCT05180240
View directory record Official record
Conditions
Acute Myocarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

NCT02792257
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dronabinol (Marinol®), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Belmont, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 17, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Reduction of Brain Neuroinflammation

NCT05066308
View directory record Official record
Conditions
Back Pain, Depressive Symptoms
Interventions
CBD, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome

NCT01786109
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Michael Camilleri
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 17, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

NCT05519111
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 17, 2026, 1:55 AM EDT
Withdrawn Phase 2 Interventional

Dronabinol for Agitation in Dementia Crossover Trial

NCT05612711
View directory record Official record
Conditions
Dementia Moderate, Dementia Severe, Agitation,Psychomotor, Behavioral Symptoms
Interventions
Dronabinol
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 17, 2026, 1:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dosing 1: Atomoxetine, AD313
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 17, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 1:55 AM EDT